The DESTINIES Study has successfully recruited over 80 world-leading experts in the area of immunology and clinical risk prioritisation. This diverse panel of clinical, academic and policy professionals bring with them unprecedented collective insight into the risks immunosuppressed patients run in terms of COVID-19 infection.

Consortium members now include affiliates of the World Health Organisation (WHO) Global Advisory Committee on Vaccine Safety (GACVS), the Coalition for Epidemic Preparedness Innovations (CEPI) Scientific Advisory Committee (SAC), the European Medicines Agency (EMA) Vaccines Working Group, the European Alliance of Associations for Rheumatology (EULAR), the Food and Drug Administration (FDA) Vaccine Advisory Panel, the Center for Disease Control and Preparedness (CDC) Advisory Committee on Immunization Practices (ACIP), the UK Joint Committee on Vaccination and Immunisation (JCVI) and the UK Scientific Advisory Group for Emergencies (SAGE). A total of 16 countries from 4 continents are currently represented.

Consortium activities are enriched by patient engagement and testimony. We have made vital inroads to charitable organisations working on behalf of the immunosuppressed to ensure that our work champions patient voices and responds to unmet need.